Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors

Prostate

Volumn 35, Issue 2, 1998, Pages 95-101

  Han, Edward Kyu Ho ^a   Lim, Jin T E ^a   Arber, Nadir ^a   Rubin, Mark A ^a   Xing, Wang Qiu ^a   Weinstein, I Bernard ^a  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

Cell cycle; Cyclin D1; Prostate cancer

Indexed keywords

CYCLIN D1; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NORTHERN BLOTTING; PRIORITY JOURNAL; PROSTATE CARCINOMA; SOUTHERN BLOTTING;

EID: 0031944598     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19980501)35:2<95::AID-PROS2>3.0.CO;2-F     Document Type: Article

References (35)

1. Hunter T, Pines J: Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell 1994;79:573-582.
2. Sherr CJ: Mammalian G1 cyclins. Cell 1994;79:551-555.
3. Weinstein IB, Zhou P: Cell cycle control gene defects and human cancer. In Bertino JR (ed): "Encyclopedia of Cancer," Vol 1. New York: Academic Press, 1996:256-267.
4. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics. CA Cancer J Clin 1997;47:5-27.
5. Isaacs W, Bova G, Morton R, Bussemakers M, Brookes J, Ewing C: Molecular biology of prostate cancer progression. Cancer Surv 1995;23:19-32.
6. Bookstein R, Rio P, Madreperla SA, Hong F, Allred C, Grizzle WE, Lee WH: Promotor deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA 1990;87:7762-7766.
7. Bookstein R, Shew J-Y, Chen P-L, Scully P, Lee WH: Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 1990;247:712-715.
8. Phillips SMA, Barton CM, Lee SJ, Morton DG, Wallace DMA, Lemoine NR, Neoptolemos JP: Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 1994;70:1252-1257.
9. Bookstein R, Macgrogan D, Hilsenbeck SG, Sharkey F, Allred DC: p53 is mutated in a subset of advanced stage prostate cancers. Cancer Res 1993;53:3369-3373.
10. Kubota Y, Shuin T, Uemura H, Fujinami K, Miyamoto H, Torigoe S, Dobashi Y, Kitamura H, Iwasaki Y, Danenberg K, Danenberg PV: Tumor suppressor gene p53 mutations in human prostate cancer. Prostate 1995;27:18-24.
11. Van Veldhuizen PJ, Sadasivan R, Garcia F, Austenfeld MS, Stephens RL: Mutant p53 expression in prostate carcinoma. Prostate 1993;22:23-30.
12. Navone NM, Tronosco P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993;85:1657-1669.
13. Gao X, Chen YQ, Wu N, Grignon DJ, Sakr W, Porter AT, Honn KV: Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene 1995;11:1395-1398.
14. Komiya A, Suzuki H, Aida S, Yatani R, Shimazaki J: Mutational analysis of CDKN2 (CDK4I/MTS1) gene in tissues and cell lines of human prostate cancer. Jpn J Cancer Res 1995;86:622-625.
15. Keyomarsi K, O'Leary N, Molnar G, Lees E, Finger HJ, Pardee AB: Cyclin E: A potential prognostic marker for breast cancer. Cancer Res 1994;54:380-385.
16. Mashal RD, Lester S, Corless C, Richie JP, Chandra R, Propert KJ, Dutta A: Expression of cell-cycle-regulated proteins in prostate cancer. Cancer Res 1996;56:4159-4163.
17. Bartkova J, Lukas J, Strauss M, Bartek J: Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 1995;10:775-778.
18. Michalides R, Hageman P, vanTineren H, Houben L, Wientiens E, Klompmaker R, Peterse H: A clinico-pathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 1996;73:728-734.
19. Nakhla AN, Rosner W: Characterization of ALVA-41 cells, a new human prostatic cancer cell line. Steroids 1994;59:586-589.
20. Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N, Narayan P: Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol 1995;31:14-24.
21. Han EK-H, Sgambato A, Wei J, Zhang Y-J, Santalla RM, Doki Y, Cacace A, Schieren I, Weinstein IB: Stable overexpression of cyclin D1 in a human mammary epithelial cell line prolongs the S-phase and inhibits growth. Oncogene 1995;10:953-961.
22. Sgambato A, Han EK-H, Schieren I, Weinstein IB: Overexpression of cyclin E in the HC11 mouse mammary epithelial cell line is associated with growth inhibition and increased expression of p27kip1. Cancer Res 1996;56:1389-1399.
23. Jiang W, Zhang Y-J, Kahn SM, Hollstgein, MC, Santella RM, Lu S-H, Harris CC, Montesano R, Weinstein IB: Altered expression of cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci USA 1993;90:9026-9030.
24. Han EK-H, Begemann M, Sgambato A, Soh J-W, Xing W-Q, Weinstein IB: Increased expression of cyclin D1 in a murine mammary epithelial cell line inhibits growth and enhances apoptosis. Cell Growth Differ 1996;7:699-710.
25. Spitnak JP, Resnick M: Clinical staging of prostatic cancer: New modalities. Urol Clin North Am 1984;11:221-235.
26. Gleason DF: Histologic grading of prostate cancer: A perspective. Hum Pathol 1992;23:273-279.
27. Arber N, Hibshoosh H, Moss SF, Sutter T, Zhang Y, Begg M, Wang S, Weinstein IB, Holt P: Increased expression of cyclin D1 in an early event in multistage colorectal carcinogenesis. Gastroenterology 1996;110:669-676.
28. Banno S, Yoshikawa K, Nakamura S, Yamamoto K, Seito T, Nitta M, Takahashi T, Ueda R, Seto M: Monoclonal antibody against PRAD1/cyclin D1 stains nuclei of tumor cells with translocation or amplification at BCL-1 Locus. Jpn J Cancer Res 1994;85:918-926.
29. Bartkova J, Lukas J, Strauss M, Bartek J: The Prad-1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas. Int J Cancer 1994;58:568-573.
30. Zhang T, Nanney LB, Luongo C, Lamps L, Heppner KJ, DuBois RN, Beauchamp RD: Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (cdk4) in intestinal adenomas from multiple intestinal neoplasia (min) mice and human familial adenomatous polyposis patients. Cancer Res 1997;57:169-175.
31. Jiang W, Kahn SM, Zhou P, Zhang Y-J, Cacace AM, Infante AS, Doi S, Santella RM, Weinstein IB: Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene 1993;8:3447-3457.
32. Zhou P, Wei J, Zhang Y-J, Kahn SM, Schieren I, Santella RM, Weinstein IB: Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene 1995;11:571-580.
33. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, Van der Riet P, Blaugrund JE, Sidransky D: Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1994;65:415-416.
34. Spruck CH III, Gonzales-Zulueta M, Shibata A, Simoneau AR, Lin M-F, Gonzales F, Tsai YC, Jones PA: p16 gene in uncultured tumors. Nature 1994;370:183-184.
35. Schauer IE, Siriwardans S, Langan TA, Sclafani RA: Cyclin D1 overexpression vs. retinoblastoma inactivation: Implications for growth control evasion in non-small cell and small cell lung cancer. Proc Natl Acad Sci USA 1994;91:7827-7831.